You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Harvard Business School
Colorcon
Moodys
Baxter

Last Updated: January 27, 2021

DrugPatentWatch Database Preview

Patent: 8,216,997

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,216,997
Title:Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Inventor(s): Seehra; Jasbir (Lexington, MA), Pearsall; Robert Scott (Woburn, MA), Kumar; Ravindra (Acton, MA)
Assignee: Acceleron Pharma, Inc. (Cambridge, MA)
Application Number:12/856,420
Patent Claims:see list of patent claims

Details for Patent 8,216,997

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 010 2001-09-17   Start Trial Acceleron Pharma, Inc. (Cambridge, MA) 2029-08-13 RX search
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 009 2001-09-17   Start Trial Acceleron Pharma, Inc. (Cambridge, MA) 2029-08-13 RX search
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 008 2001-09-17   Start Trial Acceleron Pharma, Inc. (Cambridge, MA) 2029-08-13 RX search
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 007 2001-09-17   Start Trial Acceleron Pharma, Inc. (Cambridge, MA) 2029-08-13 RX search
Amgen ARANESP darbepoetin alfa VIAL; SUBCUTANEOUS 103951 006 2001-09-17   Start Trial Acceleron Pharma, Inc. (Cambridge, MA) 2029-08-13 RX search
Amgen ARANESP darbepoetin alfa VIAL; INTRAVENOUS 103951 005 2001-09-17   Start Trial Acceleron Pharma, Inc. (Cambridge, MA) 2029-08-13 RX search
Amgen ARANESP darbepoetin alfa VIAL; INTRAVENOUS 103951 004 2001-09-17   Start Trial Acceleron Pharma, Inc. (Cambridge, MA) 2029-08-13 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 8,216,997

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2010019261   Start Trial
World Intellectual Property Organization (WIPO) 2011020045   Start Trial
United States of America 10131700   Start Trial
United States of America 10377996   Start Trial
United States of America 10689427   Start Trial
United States of America 10829532   Start Trial
United States of America 10829533   Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Baxter
Mallinckrodt
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.